Fingolimod (fingolimod hydrochloride) NDC 67877-476

NDC codes

FDA NDC Directory

Product NDC (as listed)67877-476Labeler and product segments. Claims need a package NDC.

Product NDC at billing width67877-0476Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
67877-476-30	67877047630	30 CAPSULE in 1 BOTTLE (67877-476-30)Marketed from Sep 21, 2022
67877-476-32	67877047632	7 BLISTER PACK in 1 CARTON (67877-476-32) / 7 CAPSULE in 1 BLISTER PACKMarketed from Sep 21, 2022
67877-476-33	67877047633	10 BLISTER PACK in 1 CARTON (67877-476-33) / 10 CAPSULE in 1 BLISTER PACKMarketed from Sep 21, 2022
67877-476-56	67877047656	28 CAPSULE in 1 BOTTLE (67877-476-56)Marketed from Sep 21, 2022
67877-476-58	67877047658	28 BLISTER PACK in 1 CARTON (67877-476-58) / 14 CAPSULE in 1 BLISTER PACK (67877-476-14)Marketed from Sep 21, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fingolimod
Generic name (nonproprietary): fingolimod hydrochloride
Active ingredients: Fingolimod hydrochloride — .5 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Ascend Laboratories, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 208004
Marketing start: Sep 21, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Sphingosine 1-Phosphate Receptor Modulators (Mechanism)
Identifiers: Product ID 67877-476_d2f337fa-908a-4ae9-bcfd-59dcc4353705SPL ID d2f337fa-908a-4ae9-bcfd-59dcc4353705SPL set ID 0f638feb-6986-41e4-8f9c-2e6b84a5bb44RxCUI 1012895UNII G926EC510T
Pharmacologic class: Sphingosine 1-phosphate Receptor Modulator

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N467877047630 followed by a unit qualifier and the quantity

Package 67877-0476-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 27, 2026.

Indications (excerpt from the label)

Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. Fingolimod capsules are a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 208004

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 208004
Product	Strength	Form · route	Labeler	Product NDC
Fingolimod	Fingolimod hydrochloride .5 mg/1	CapsuleOral	CivicaScript LLC	82249-385